tiprankstipranks
Advertisement
Advertisement

GPCR Stock Latest News

Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright
The FlyStructure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright
6d ago
GPCR
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged
PremiumRatings
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged
9d ago
GPCR
Structure Therapeutics announces ACCESS trial data published in Nature Medicine
PremiumThe Fly
Structure Therapeutics announces ACCESS trial data published in Nature Medicine
11d ago
GPCR
Analyst Maintains Buy on Strong Aleniglipron Data and 2026 Catalysts, Modestly Trimming Price Target to $104
PremiumRatings
Analyst Maintains Buy on Strong Aleniglipron Data and 2026 Catalysts, Modestly Trimming Price Target to $104
1M ago
GPCR
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program
PremiumCompany Announcements
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program
1M ago
8K
GPCR
Canaccord starts Structure Therapeutics on oral weight loss pipeline
PremiumThe FlyCanaccord starts Structure Therapeutics on oral weight loss pipeline
2M ago
GPCR
Structure Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Structure Therapeutics initiated with a Buy at Canaccord
2M ago
GPCR
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market
Premium
Market News
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market
2M ago
LLY
PFE
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer
PremiumCompany Announcements
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer
2M ago
8K
GPCR
Structure Therapeutics appoints Matthew Lang as COO
PremiumThe Fly
Structure Therapeutics appoints Matthew Lang as COO
2M ago
GPCR
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
PremiumRatings
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
3M ago
GPCR
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
PremiumThe Fly
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
3M ago
GPCR
Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
PremiumRatingsBuy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
3M ago
GPCR
Structure’s GLP-1 pill could put company on M&A radar, Barron’s says
Premium
The Fly
Structure’s GLP-1 pill could put company on M&A radar, Barron’s says
3M ago
LLY
NVO
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results
Premium
Company Announcements
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results
3M ago
8K
GPCR
Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study
PremiumThe Fly
Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study
3M ago
GPCR
Leveraging External Amylin Validation: Positioning Structure Therapeutics’ Amylin and Oral GLP‑1 Platform for Combination-Driven Upside
PremiumRatings
Leveraging External Amylin Validation: Positioning Structure Therapeutics’ Amylin and Oral GLP‑1 Platform for Combination-Driven Upside
3M ago
GPCR
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
PremiumThe Fly
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
4M ago
GPCR
Structure Therapeutics price target lowered to $113 from $120 at Citizens
PremiumThe Fly
Structure Therapeutics price target lowered to $113 from $120 at Citizens
4M ago
GPCR
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
PremiumRatingsBuy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
4M ago
GPCR
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
Premium
The Fly
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
5M ago
V
CL
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
Premium
The Fly
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
5M ago
GPCR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >